Please assess the completion status of the following clinical trial:

Trial Title: Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Must be competent and able to comprehend, sign, and date an Ethics Committee (EC) or Institutional Review Board approved Informed Consent Form (ICF) before performance of any study-specific procedures or tests;~2. Is ≥18 years or the minimum legal adult age (whichever is greater) and ≤75 years (at Screening);~3. Newly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm, based on the World Health Organization (WHO) 2008 classification (at Screening);~4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (at the time the participant signs their first ICF);~5. Presence of FLT3-ITD activating mutation in bone marrow (allelic ratio of ≥3% FLT3-ITD/total FLT3);~6. Participant is receiving standard 7+3 induction chemotherapy regimen as specified in the protocol;~7. Adequate renal function defined as:~   a. Creatinine clearance \>50 mL/min, as calculated with the modified Cockcroft Gault equation~8. Adequate hepatic function defined as:~   1. Total serum bilirubin (TBL) ≤1.5 × upper limit of normal (ULN) unless the participant has documented Gilbert's syndrome or the increase is related to increased unconjugated (indirect) bilirubin due to hemolysis;~  2. Serum alkaline phosphatase, aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 × ULN;~9. Serum electrolytes within normal limits: potassium, calcium (total, or corrected for serum albumin in case of hypoalbuminemia or ionized calcium) and magnesium. If outside of normal limits, participant will be eligible when electrolytes are corrected;~10. If a woman of childbearing potential, must have a negative serum pregnancy test upon entry into this study and must be willing to use highly effective birth control upon enrollment, during the treatment period and for 6 months following the last dose of investigational drug or cytarabine, whichever is later. A woman is considered of childbearing potential following menarche and until becoming postmenopausal (no menstrual period for a minimum of 12 months);~11. If male, must be surgically sterile or willing to use highly effective birth control upon enrollment, during the treatment period, and for 6 months following the last dose of investigational drug or cytarabine, whichever is later.~Exclusion Criteria:~1. Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) positive leukemia (ie, chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).~2. Diagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms;~3. Prior treatment for AML, except for the following allowances:~   * Leukapheresis;~  * Treatment for hyperleukocytosis with hydroxyurea;~  * Cranial radiotherapy for central nervous system (CNS) leukostasis;~  * Prophylactic intrathecal chemotherapy;~  * Growth factor/cytokine support;~4. Prior treatment with quizartinib or other FLT3-ITD inhibitors;~5. Prior treatment with any investigational drug or device within 30 days prior to Randomization (within 2 weeks for investigational or approved immunotherapy) or currently participating in other investigational procedures;~6. History of known CNS leukemia, including cerebrospinal fluid positive for AML blasts; lumbar puncture is recommended for participants with symptoms of CNS leukemia to rule out extramedullary CNS involvement;~7. History of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for at least 2 years;~8. Uncontrolled or significant cardiovascular disease, including any of the following:~   * Bradycardia of less than 50 beats per minute, unless the participant has a pacemaker;~  * Fridericia's Heart Rate Correction Formula (QTcF) interval \>450 msec;~  * Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome);~  * Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg;~  * History of clinically relevant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes);~  * History of second (Mobitz II) or third degree heart block (participants with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker);~  * History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening;~  * History of New York Heart Association Class 3 or 4 heart failure;~  * Known history of left ventricular ejection fraction (LVEF) ≤45% or less than the institutional lower limit of normal;~  * Complete left bundle branch block;~9. Active acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy;~10. Known active clinically relevant liver disease (eg, active hepatitis B, or active hepatitis C);~11. Known history of human immunodeficiency virus (HIV). Participants should be tested for HIV prior to Randomization if required by local regulations or EC;~12. History of hypersensitivity to any excipients in the quizartinib/placebo tablets;~13. Females who are pregnant or breastfeeding;~14. Otherwise considered inappropriate for the study by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Chemotherapy plus quizartinib (Type: EXPERIMENTAL): Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by the experimental drug quizartinib~Consolidation: up to 4 cycles of cytarabine followed by the experimental drug quizartinib and/or hematopoeitic stem cell transplant~Continuation: up to 36 cycles with the experimental drug quizartinib
- Chemotherapy plus placebo (Type: ACTIVE_COMPARATOR): Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by placebo~Consolidation: up to 4 cycles of cytarabine followed by placebo and/or hematopoeitic stem cell transplant~Continuation: up to 36 cycles with placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).